You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

 

Online download statistics by month:

Online download statistics by month: March 2021 to March 2024

AbstractFullPdf
Mar 2021268268214
Apr 2021529529199
May 202142642699
Jun 2021315315129
Jul 202125325390
Aug 202126426499
Sep 202119719789
Oct 202120920994
Nov 202124724887
Dec 2021214215280
Jan 202219720673
Feb 202218520175
Mar 202221522098
Apr 202219621174
May 202215416675
Jun 202215516479
Jul 202212915071
Aug 2022240254107
Sep 202216919696
Oct 2022161201119
Nov 2022310318121
Dec 202213914464
Jan 202313013557
Feb 202315315562
Mar 202312913345
Apr 202318218384
May 202318318471
Jun 202324024166
Jul 202312312441
Aug 202310310538
Sep 202312312551
Oct 202314614671
Nov 202319919940
Dec 202313613757
Jan 2024132135122
Feb 2024888836
Mar 2024105111137
Total734475563410